1. Home
  2. PRSO vs BIVI Comparison

PRSO vs BIVI Comparison

Compare PRSO & BIVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Peraso Inc.

PRSO

Peraso Inc.

HOLD

Current Price

$0.37

Market Cap

13.4M

Sector

Technology

ML Signal

HOLD

Logo BioVie Inc.

BIVI

BioVie Inc.

HOLD

Current Price

$1.25

Market Cap

12.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PRSO
BIVI
Founded
2008
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Semiconductors
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
13.4M
12.7M
IPO Year
2000
2013

Fundamental Metrics

Financial Performance
Metric
PRSO
BIVI
Price
$0.37
$1.25
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
★ $5.26
AVG Volume (30 Days)
★ 11.3M
193.8K
Earning Date
11-09-2026
11-09-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 81.23
74.83
EPS
★ N/A
N/A
Revenue
★ $14,573,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$191.73
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 5.99
N/A
52 Week Low
$0.36
$0.82
52 Week High
$2.10
$3.79

Technical Indicators

Market Signals
Indicator
PRSO
BIVI
Relative Strength Index (RSI) 42.56 40.77
Support Level $0.36 $1.14
Resistance Level $0.52 $1.32
Average True Range (ATR) 0.05 0.11
MACD 0.00 0.01
Stochastic Oscillator 6.18 34.21

Price Performance

Historical Comparison
PRSO
BIVI

About PRSO Peraso Inc.

Peraso Inc is a fabless semiconductor company focused on the development and sale of: i) millimeter wavelength wireless technology, or mmWave, semiconductor devices and antenna modules based on its proprietary semiconductor devices, and ii) performance of non-recurring engineering, or NRE, services and licensing of intellectual property, or IP. The company's primary focus is the development of mmWave, which is generally described as the frequency band from 24 Gigahertz, or GHz to 300 GHz. Geographically, the company generates revenue from the United States, Hong Kong, Taiwan, Europe, and the Rest of the World.

About BIVI BioVie Inc.

BioVie Inc is a clinical-stage company developing drug therapies for the treatment of neurological and neurodegenerative disorders and liver disease. Its therapeutic areas include Alzheimer's, Parkinson's, Long COVID, Ascites, Longevity, and Epigenetics. In liver disease, its investigational drug candidate BIV201 (continuous infusion terlipressin) was granted FDA Fast Track status and FDA Orphan Drug designation for ascites due to all etiologies except cancer. BIV201 is being evaluated as a treatment option for patients suffering from life-threatening complications of liver cirrhosis and ascites due to hepatitis, nonalcoholic steatohepatitis, and alcoholism.

Share on Social Networks: